Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSA with or without PD-1 blockade and Poly ICLC in advanced solid tumors
NCT04116320Phase 1Terminated
- Start
- Nov 2019
- Primary completion
- Aug 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of poly iclc in melanoma, breast cancer, Merkel cell carcinoma (MCC) and 10 more (4 cohorts). Primary endpoints: Safety and toxicity of FUSA administered alone or in combination with PD-1 antibody blockade at 30 days and Increased CD8+ T cell infiltration of spot FUSA-treated metastasis at Day 43. Started Nov 2019; status: terminated.
02
Drugs
poly iclc
03
Conditions
melanomabreast cancerMerkel cell carcinoma (MCC)squamous cell carcinoma (SCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04116320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116320.